SCHOTT Pharma AG & Co. KGaA

SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes

SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes

SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations

SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility

Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda

SCHOTT Pharma AG & Co. KGaA: Dr. Jens Schulte, sell